Analysis shows differing trajectories of special access policies for drugs and devices across regions, implying tailored approaches in policy evolution.
China’s special access policies for unapproved drugs and medical devices represent a key institutional innovation in its healthcare regulatory system. In recent years, tailored versions of this policy have been implemented in Hainan Lecheng, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), and Beijing Tianzhu, each exhibiting differentiated trajectories in institutional design and management mechanisms. This study identifies a pattern of policy evolution termed Strategy-Embedded Diffusion, a model wherein the central government does not mandate a uniform policy model, but strategically deploys this tool to different strategic regions in alignment with national objectives. To analyze this phenomenon, this study develops a three-tiered interactive framework encompassing central delegation, local innovation, and social feedback. A comparative case analysis reveals that: the central government delineates distinct scopes of authorization based on each region’s strategic positioning and risk tolerances; local governments engage in selective learning and institutional reproduction tailored to local conditions; and key societal stakeholders actively shape policy refinement through continuous feedback.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: